Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report  
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (JPY)
Sales 2019 916 B
EBIT 2019 -
Net income 2019 62 838 M
Finance 2019 344 B
Yield 2019 1,37%
Sales 2020 930 B
EBIT 2020 -
Net income 2020 71 119 M
Finance 2020 396 B
Yield 2020 1,37%
P/E ratio 2019 53,28
P/E ratio 2020 47,41
EV / Sales2019 3,59x
EV / Sales2020 3,49x
Capitalization 3 636 B
More Financials
Company
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.7%): prescription medicines (93% of net sales) and OTC medicines (7%) primarily for the treatment of thrombotic disorders,... 
Sector
Pharmaceuticals
Calendar
04/25Earnings Release
More about the company
Surperformance© ratings of DAIICHI SANKYO COMPANY, LI
Trading Rating : Investor Rating :
More Ratings
Latest news on DAIICHI SANKYO COMPANY, LI
04/19DAIICHI SANKYO : LifeArc licenses discovery programme to Daiichi Sankyo
AQ
04/16DAIICHI SANKYO : Launches 'Tarlige Tablets' for Pain Treatment in Japan
AQ
04/14DAIICHI SANKYO : Launches “Tarlige® Tablets” for Pain Treatment in J..
PU
04/12DAIICHI SANKYO : Supreme Court reserves order on Daiichi Sankyo plea
AQ
04/08DAIICHI SANKYO : EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE ..
PU
04/06DAIICHI : s Xospata rival pushed back by FDA as it combs through new data
AQ
04/05DAIICHI SANKYO : SC to jail ex-Ranbaxy promoters if found guilty of not paying D..
AQ
04/04DAIICHI SANKYO : Provides Update on Ongoing FDA Review for Quizartinib for Treat..
PU
04/03DAIICHI SANKYO : EMA Validates Daiichi Sankyo's Marketing Authorization Applicat..
PU
04/01DAIICHI SANKYO : Pharma taps new CEO just as it unveils a big tie-up with AstraZ..
AQ
More news
Analyst Recommendations on DAIICHI SANKYO COMPANY, LI
More recommendations
Sector news : Pharmaceuticals - NEC
11:31aBIOGEN : dips as strategy post Alzheimer's setback fails to impress
RE
11:25aBIOGEN : dips as strategy post Alzheimer's setback fails to impress
RE
09:08aGLOBAL MARKETS LIVE : Samsung, Wirecard, Boeing, Nissan…
07:42aBIOGEN : Earnings Rise Helped by Equity Investment
DJ
06:16aAMGEN : Novartis shares rise as Swiss drugmaker lifts 2019 profit outlook
RE
More sector news : Pharmaceuticals - NEC
Chart DAIICHI SANKYO COMPANY, LIMITED
Duration : Period :
DAIICHI SANKYO COMPANY, LIMITED Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DAIICHI SANKYO COMPANY, LI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 5 530  JPY
Spread / Average Target 7,8%
EPS Revisions
Managers
NameTitle
Joji Nakayama Chairman & CEO
Sunao Manabe President, COO & Representative Director
Toshiaki Sai CFO, Representative Director & Vice President
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Katsumi Fujimoto Director & Senior Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY, LIMITED52.23%32 501
JOHNSON & JOHNSON6.80%372 522
ROCHE HOLDING LTD.10.11%227 132
PFIZER-9.69%218 852
NOVARTIS4.88%195 750
MERCK AND COMPANY-2.37%192 697